Michael B Keller, David Newman, Muhtadi Alnababteh, Lucia Ponor, Pali Shah, Joby Matthews, Hyesik Kong, Temesgen Andargie, Woojin Park, Ananth Charya, Helen Luikart, Shambhu Aryal, Steven D Nathan, Jonathan B Orens, Kiran K Khush, Moon Jang, Sean Agbor-Enoh
BACKGROUND: Lung transplant recipients are traditionally monitored with pulmonary function testing (PFT) and lung biopsy to detect post-transplant complications and guide treatment. Plasma donor-derived cell free DNA (dd-cfDNA) is a novel molecular approach of assessing allograft injury, including subclinical allograft dysfunction. The aim of this study was to determine if episodes of extreme molecular injury (EMI) in lung transplant recipients increases the risk of CLAD or death. METHODS: This multicenter prospective cohort study included 238 lung transplant recipients...
May 3, 2024: Journal of Heart and Lung Transplantation